83 related articles for article (PubMed ID: 2807151)
1. Medullary thyroid carcinoma: prognosis of familial versus nonfamilial disease and the role of radiotherapy.
Samaan NA; Schultz PN; Hickey RC
Horm Metab Res Suppl; 1989; 21():21-5. PubMed ID: 2807151
[TBL] [Abstract][Full Text] [Related]
2. Medullary thyroid carcinoma: prognosis of familial versus sporadic disease and the role of radiotherapy.
Samaan NA; Schultz PN; Hickey RC
J Clin Endocrinol Metab; 1988 Oct; 67(4):801-5. PubMed ID: 2901430
[TBL] [Abstract][Full Text] [Related]
3. Prognostic variables and calcitonin in medullary thyroid cancer.
Clark JR; Fridman TR; Odell MJ; Brierley J; Walfish PG; Freeman JL
Laryngoscope; 2005 Aug; 115(8):1445-50. PubMed ID: 16094121
[TBL] [Abstract][Full Text] [Related]
4. Medullary thyroid carcinoma experienced at Kanazawa University Hospital.
Mizukami Y; Nonomura A; Michigishi T; Noguchi M; Ohtake S; Nakamura S; Ishizaki T
J Surg Oncol; 1996 Jan; 61(1):27-33. PubMed ID: 8544456
[TBL] [Abstract][Full Text] [Related]
5. Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients.
Saad MF; Ordonez NG; Rashid RK; Guido JJ; Hill CS; Hickey RC; Samaan NA
Medicine (Baltimore); 1984 Nov; 63(6):319-42. PubMed ID: 6503683
[TBL] [Abstract][Full Text] [Related]
6. [Usefulness of serum calcitonin, CEA and AFP assays in the early detection of medullary thyroid carcinoma relapse].
Łacka K; Michałek K; Majewski P
Wiad Lek; 2002; 55(7-8):394-403. PubMed ID: 12428567
[TBL] [Abstract][Full Text] [Related]
7. [The prognostic importance of calcitonin screening in familial medullary thyroid carcinoma].
Raue F; Geiger S; Buhr H; Frank-Raue K; Ziegler R
Dtsch Med Wochenschr; 1993 Jan; 118(3):49-52. PubMed ID: 8425457
[TBL] [Abstract][Full Text] [Related]
8. Long-term prognosis of medullary thyroid carcinoma.
Rendl G; Manzl M; Hitzl W; Sungler P; Pirich C
Clin Endocrinol (Oxf); 2008 Sep; 69(3):497-505. PubMed ID: 18331612
[TBL] [Abstract][Full Text] [Related]
9. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group.
Chatal JF; Campion L; Kraeber-Bodéré F; Bardet S; Vuillez JP; Charbonnel B; Rohmer V; Chang CH; Sharkey RM; Goldenberg DM; Barbet J;
J Clin Oncol; 2006 Apr; 24(11):1705-11. PubMed ID: 16549819
[TBL] [Abstract][Full Text] [Related]
10. Calcitonin gene-related peptide as a tumor marker for medullary thyroid carcinoma.
Takami H; Ito K
Int Surg; 1992; 77(3):181-5. PubMed ID: 1399365
[TBL] [Abstract][Full Text] [Related]
11. Familial and sporadic medullary thyroid carcinoma: clinical and immunohistological findings.
Ekblom M; Välimäki M; Pelkonen R; Jansson R; Sivula A; Franssila K
Q J Med; 1987 Nov; 65(247):899-910. PubMed ID: 2901773
[TBL] [Abstract][Full Text] [Related]
12. Long-term survival in sporadic and familial medullary thyroid carcinoma with special reference to clinical characteristics as prognostic factors. The Swedish MTC Study Group.
Bergholm U; Adami HO; Bergström R; Bäckdahl M; Akerström G
Acta Chir Scand; 1990 Jan; 156(1):37-46. PubMed ID: 2321439
[TBL] [Abstract][Full Text] [Related]
13. Circulating calcitonin and carcinoembryonic antigen m-RNA detected by RT-PCR as tumour markers in medullary thyroid carcinoma.
Bojunga J; Dragan C; Schumm-Draeger PM; Usadel KH; Kusterer K
Br J Cancer; 2001 Nov; 85(10):1546-50. PubMed ID: 11720443
[TBL] [Abstract][Full Text] [Related]
14. [Medullary carcinoma of the thyroid: diagnosis and therapy].
Giuffrida D; Ferraù F; Bordonaro R; Mattina M; Priolo D; Aiello RA; Cordio S; Motta S; Failla G
Clin Ter; 2000; 151(1):29-35. PubMed ID: 10822879
[TBL] [Abstract][Full Text] [Related]
15. MIBG for diagnosis and therapy of medullary thyroid carcinoma: is there still a role?
Castellani MR; Seregni E; Maccauro M; Chiesa C; Aliberti G; Orunesu E; Bombardieri E
Q J Nucl Med Mol Imaging; 2008 Dec; 52(4):430-40. PubMed ID: 19088696
[TBL] [Abstract][Full Text] [Related]
16. [Prognostic factors of survival in medullary cancers of the thyroid. Apropos of 51 cases. Clinical, biochemical and immunocytochemical study].
Goudet P; Rogissart F; Petit JM; Vaillant G; Durnerin I; Fraisse J; Justrabo E; Verges B; Cougard P
Ann Chir; 1996; 50(1):23-9. PubMed ID: 8734273
[TBL] [Abstract][Full Text] [Related]
17. Long term prognosis of medullary thyroid carcinoma in 39 patients.
Voutilainen PE; Multanen M; Haapiainen RK; Haglund CH; Sane T; Sivula AH
Ann Chir Gynaecol; 2000; 89(4):292-7. PubMed ID: 11204961
[TBL] [Abstract][Full Text] [Related]
18. Can sporadic medullary thyroid carcinoma be biochemically predicted? Prospective analysis of 66 operated patients with elevated serum calcitonin levels.
Iacobone M; Niccoli-Sire P; Sebag F; De Micco C; Henry JF
World J Surg; 2002 Aug; 26(8):886-90. PubMed ID: 12016469
[TBL] [Abstract][Full Text] [Related]
19. Association of mitochondrial DNA transversion mutations with familial medullary thyroid carcinoma/multiple endocrine neoplasia type 2 syndrome.
Abu-Amero KK; Alzahrani AS; Zou M; Shi Y
Oncogene; 2006 Feb; 25(5):677-84. PubMed ID: 16205644
[TBL] [Abstract][Full Text] [Related]
20. Management and outcome of recurrent well-differentiated thyroid carcinoma.
Palme CE; Waseem Z; Raza SN; Eski S; Walfish P; Freeman JL
Arch Otolaryngol Head Neck Surg; 2004 Jul; 130(7):819-24. PubMed ID: 15262757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
